Publications
-
Cd14 SNPs regulate the innate immune response.
Liu HH,
Hu Y, Zheng M, Suhoski MM, Engleman EG, Dill DL, Hudnall M, Wang J, Spolski R, Leonard WJ, Peltz G.
Mol Immunol.
2012;
51
(2):
112-27
-
Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants.
Scandling JD,
Busque S, Dejbakhsh-Jones S, Benike C, Sarwal M, Millan MT, Shizuru JA, Lowsky R, Engleman EG, Strober S.
Am J Transplant.
2012;
12
(5):
1133-45
-
B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies.
Winer DA,
Winer S, Shen L, Wadia PP, Yantha J, Paltser G, Tsui H, Wu P, Davidson MG, Alonso MN, Leong HX, Glassford A, Caimol M, Kenkel JA, Tedder TF, McLaughlin T, Miklos DB, Dosch HM, Engleman EG.
Nat Med.
2011;
17
(5):
610-7
-
Plasmacytoid dendritic cell dichotomy: identification of IFN-α producing cells as a phenotypically and functionally distinct subset.
Björck P,
Leong HX, Engleman EG.
J Immunol.
2011;
186
(3):
1477-85
-
T(H)1, T(H)2, and T(H)17 cells instruct monocytes to differentiate into specialized dendritic cell subsets.
Alonso MN,
Wong MT, Zhang AL, Winer D, Suhoski MM, Tolentino LL, Gaitan J, Davidson MG, Kung TH, Galel DM, Nadeau KC, Kim J, Utz PJ, Söderström K, Engleman EG.
Blood.
2011;
118
(12):
3311-20
-
The role of vanin-1 and oxidative stress-related pathways in distinguishing acute and chronic pediatric ITP.
Zhang B,
Lo C, Shen L, Sood R, Jones C, Cusmano-Ozog K, Park-Snyder S, Wong W, Jeng M, Cowan T, Engleman EG, Zehnder JL.
Blood.
2011;
117
(17):
4569-79
-
Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host.
Tseng WW,
Winer D, Kenkel JA, Choi O, Shain AH, Pollack JR, French R, Lowy AM, Engleman EG.
Clin Cancer Res.
2010;
16
(14):
3684-95
-
Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis.
Söderström K,
Stein E, Colmenero P, Purath U, Müller-Ladner U, de Matos CT, Tarner IH, Robinson WH, Engleman EG.
Proc Natl Acad Sci U S A.
2010;
107
(29):
13028-33
-
Regulation of human Th9 differentiation by type I interferons and IL-21.
Wong MT,
Ye JJ, Alonso MN, Landrigan A, Cheung RK, Engleman E, Utz PJ.
Immunol Cell Biol.
2010;
88
(6):
624-31
-
Chemoselective ligation in the functionalization of polysaccharide-based particles.
Beaudette TT,
Cohen JA, Bachelder EM, Broaders KE, Cohen JL, Engleman EG, Fréchet JM.
J Am Chem Soc.
2009;
131
(30):
10360-1
-
Ineffective vaccination against solid tumors can be enhanced by hematopoietic cell transplantation.
Filatenkov A,
Müller AM, Tseng WW, Dejbakhsh-Jones S, Winer D, Luong R, Shizuru JA, Engleman EG, Strober S.
J Immunol.
2009;
183
(11):
7196-203
-
T-cell activation by antigen-loaded pH-sensitive hydrogel particles in vivo: the effect of particle size.
Cohen JA,
Beaudette TT, Tseng WW, Bachelder EM, Mende I, Engleman EG, Fréchet JM.
Bioconjug Chem.
2009;
20
(1):
111-9
-
Plasmacytoid dendritic cells take up opsonized antigen leading to CD4+ and CD8+ T cell activation in vivo.
Björck P,
Beilhack A, Herman EI, Negrin RS, Engleman EG.
J Immunol.
2008;
181
(6):
3811-7
-
Tolerance and chimerism after renal and hematopoietic-cell transplantation.
Scandling JD,
Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA, Hoppe RT, Lowsky R, Engleman EG, Strober S.
N Engl J Med.
2008;
358
(4):
362-8
-
Incorporation of CpG oligonucleotide ligand into protein-loaded particle vaccines promotes antigen-specific CD8 T-cell immunity.
Standley SM,
Mende I, Goh SL, Kwon YJ, Beaudette TT, Engleman EG, Fréchet JM.
Bioconjug Chem.
2007 Jan-Feb;
18
(1):
77-83
-
Breaking self-tolerance to tumor-associated antigens by in vivo manipulation of dendritic cells.
Mende I,
Engleman EG.
Methods Mol Biol.
2007:
380
457-68
-
Natural killer cells trigger differentiation of monocytes into dendritic cells.
Zhang AL,
Colmenero P, Purath U, Teixeira de Matos C, Hueber W, Klareskog L, Tarner IH, Engleman EG, Söderström K.
Blood.
2007;
110
(7):
2484-93
-
Orthotopic mouse model of colorectal cancer.
Tseng W,
Leong X, Engleman E.
J Vis Exp.
2007;
(10):
484
-
Qa-1(b)-dependent modulation of dendritic cell and NK cell cross-talk in vivo.
Colmenero P,
Zhang AL, Qian T, Lu L, Cantor H, Söderström K, Engleman EG.
J Immunol.
2007;
179
(7):
4608-15
-
Flk2+ myeloid progenitors are the main source of Langerhans cells.
Mende I,
Karsunky H, Weissman IL, Engleman EG, Merad M.
Blood.
2006;
107
(4):
1383-90
-
Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy.
Saji H,
Song W, Furumoto K, Kato H, Engleman EG.
Clin Cancer Res.
2006;
12
(8):
2568-74
-
Breaking tolerance to tumors with dendritic cell-based immunotherapy.
Mende I,
Engleman EG.
Ann N Y Acad Sci.
2005:
1058
96-104
-
Developmental origin of interferon-alpha-producing dendritic cells from hematopoietic precursors.
Karsunky H,
Merad M, Mende I, Manz MG, Engleman EG, Weissman IL.
Exp Hematol.
2005;
33
(2):
173-81
-
In vivo manipulation of dendritic cells overcomes tolerance to unmodified tumor-associated self antigens and induces potent antitumor immunity.
Okano F,
Merad M, Furumoto K, Engleman EG.
J Immunol.
2005;
174
(5):
2645-52
-
DC-based cancer vaccines: lessons from clinical trials.
Brody JD,
Engleman EG.
Cytotherapy.
2004;
6
(2):
122-7
-
Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease.
Merad M,
Hoffmann P, Ranheim E, Slaymaker S, Manz MG, Lira SA, Charo I, Cook DN, Weissman IL, Strober S, Engleman EG.
Nat Med.
2004;
10
(5):
510-7
-
Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.
Furumoto K,
Soares L, Engleman EG, Merad M.
J Clin Invest.
2004;
113
(5):
774-83
-
Two isoforms of otubain 1 regulate T cell anergy via GRAIL.
Soares L,
Seroogy C, Skrenta H, Anandasabapathy N, Lovelace P, Chung CD, Engleman E, Fathman CG.
Nat Immunol.
2004;
5
(1):
45-54
-
Using signaling pathways to overcome immune tolerance to tumors.
Engleman EG,
Brody J, Soares L.
Sci STKE.
2004;
2004
(241):
pe28
-
Dendritic cell-based cancer immunotherapy.
Engleman EG,
Semin Oncol.
2003;
30
(3 Suppl 8):
23-9
-
Induction of immunity to tumor-associated antigens following dendritic cell vaccination of cancer patients.
Engleman EG,
Fong L.
Clin Immunol.
2003;
106
(1):
10-5
-
Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
Timmerman JM,
Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R.
Blood.
2002;
99
(5):
1517-26
-
In vivo manipulation of dendritic cells to induce therapeutic immunity.
Merad M,
Sugie T, Engleman EG, Fong L.
Blood.
2002;
99
(5):
1676-82
-
Langerhans cells renew in the skin throughout life under steady-state conditions.
Merad M,
Manz MG, Karsunky H, Wagers A, Peters W, Charo I, Weissman IL, Cyster JG, Engleman EG.
Nat Immunol.
2002;
3
(12):
1135-41
-
Productive infection of plasmacytoid dendritic cells with human immunodeficiency virus type 1 is triggered by CD40 ligation.
Fong L,
Mengozzi M, Abbey NW, Herndier BG, Engleman EG.
J Virol.
2002;
76
(21):
11033-41
-
Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy.
Fong L,
Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG.
Proc Natl Acad Sci U S A.
2001;
98
(15):
8809-14
-
Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice.
Scappaticci FA,
Smith R, Pathak A, Schloss D, Lum B, Cao Y, Johnson F, Engleman EG, Nolan GP.
Mol Ther.
2001;
3
(2):
186-96
-
Dendritic cell development from common myeloid progenitors.
Manz MG,
Traver D, Akashi K, Merad M, Miyamoto T, Engleman EG, Weissman IL.
Ann N Y Acad Sci.
2001:
938
167-73; discussion 173-4
-
Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy.
Fong L,
Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, Engleman EG.
J Immunol.
2001;
167
(12):
7150-6
-
Dendritic cells injected via different routes induce immunity in cancer patients.
Fong L,
Brockstedt D, Benike C, Wu L, Engleman EG.
J Immunol.
2001;
166
(6):
4254-9
-
Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma.
Davis TA,
Hsu FJ, Caspar CB, van Beckhoven A, Czerwinsk DK, Liles TM, Taidi B, Benike CJ, Engleman EG, Levy R.
Biol Blood Marrow Transplant.
2001;
7
(9):
517-22
-
Clinical transplantation tolerance twelve years after prospective withdrawal of immunosuppressive drugs: studies of chimerism and anti-donor reactivity.
Strober S,
Benike C, Krishnaswamy S, Engleman EG, Grumet FC.
Transplantation.
2000;
69
(8):
1549-54
-
Dendritic cells in cancer immunotherapy.
Fong L,
Engleman EG.
Annu Rev Immunol.
2000:
18
245-73
-
Development of CD8alpha-positive dendritic cells from a common myeloid progenitor.
Traver D,
Akashi K, Manz M, Merad M, Miyamoto T, Engleman EG, Weissman IL.
Science.
2000;
290
(5499):
2152-4
-
Differentiation of myeloid dendritic cells into CD8alpha-positive dendritic cells in vivo.
Merad M,
Fong L, Bogenberger J, Engleman EG.
Blood.
2000;
96
(5):
1865-72
-
Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.
Liso A,
Stockerl-Goldstein KE, Auffermann-Gretzinger S, Benike CJ, Reichardt V, van Beckhoven A, Rajapaksa R, Engleman EG, Blume KG, Levy R.
Biol Blood Marrow Transplant.
2000;
6
(6):
621-7
-
Comparison of primary sensitization of naive human T cells to varicella-zoster virus peptides by dendritic cells in vitro with responses elicited in vivo by varicella vaccination.
Jenkins DE,
Yasukawa LL, Bergen R, Benike C, Engleman EG, Arvin AM.
J Immunol.
1999;
162
(1):
560-7
-
Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.
Reichardt VL,
Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, Blume KG, Levy R.
Blood.
1999;
93
(7):
2411-9
-
Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration.
Brockstedt DG,
Podsakoff GM, Fong L, Kurtzman G, Mueller-Ruchholtz W, Engleman EG.
Clin Immunol.
1999;
92
(1):
67-75
-
A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients.
Kundu SK,
Engleman E, Benike C, Shapero MH, Dupuis M, van Schooten WC, Eibl M, Merigan TC.
AIDS Res Hum Retroviruses.
1998;
14
(7):
551-60
-
Donor blood monocytes but not T or B cells facilitate long-term allograft survival after total lymphoid irradiation.
Hayamizu K,
Zeng D, Huie P, Garcia-Ojeda ME, Bloch DA, Fong L, Engleman EG, Sibley RK, Strober S.
Transplantation.
1998;
66
(5):
585-93
-
Isolation and utilization of human dendritic cells from peripheral blood to assay an in vitro primary immune response to varicella-zoster virus peptides.
Jenkins DE,
Yasukawa LL, Benike CJ, Engleman EG, Arvin AM.
J Infect Dis.
1998:
178 Suppl 1
S39-42
-
V7 (CD101) ligation inhibits TCR/CD3-induced IL-2 production by blocking Ca2+ flux and nuclear factor of activated T cell nuclear translocation.
Soares LR,
Tsavaler L, Rivas A, Engleman EG.
J Immunol.
1998;
161
(1):
209-17
-
Allogeneic dendritic cell induction of HIV-specific cytotoxic T lymphocyte responses from T cells of HIV type 1-infected and uninfected individuals.
Dupuis M,
Peshwa MV, Benike C, Kundu SK, Engleman EG, Van Schooten WC, Merigan TC.
AIDS Res Hum Retroviruses.
1997;
13
(1):
33-9
-
Dendritic cells: potential role in cancer therapy.
Engleman EG,
Cytotechnology.
1997;
25
(1-3):
1-8
-
Differential response of CD4+ V7+ and CD4+ V7- T cells to T cell receptor-dependent signals: CD4+ V7+ T cells are co-stimulation independent and anti-V7 antibody blocks the induction of anergy by bacterial superantigen.
Soares LR,
Rivas A, Ruegg C, Engleman EG.
Eur J Immunol.
1997;
27
(6):
1413-21
-
Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer.
Fong L,
Ruegg CL, Brockstedt D, Engleman EG, Laus R.
J Immunol.
1997;
159
(7):
3113-7
-
Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide.
Kim DT,
Mitchell DJ, Brockstedt DG, Fong L, Nolan GP, Fathman CG, Engleman EG, Rothbard JB.
J Immunol.
1997;
159
(4):
1666-8
-
Ligation of the V7 molecule on T cells blocks anergy induction through a CD28-independent mechanism.
Soares LR,
Rivas A, Tsavaler L, Engleman EG.
J Immunol.
1997;
159
(3):
1115-24
-
Immune regulation: a critical link between NK cells and CTLs.
Kos FJ,
Engleman EG.
Immunol Today.
1996;
17
(4):
174-6
-
Role of natural killer cells in the generation of influenza virus-specific cytotoxic T cells.
Kos FJ,
Engleman EG.
Cell Immunol.
1996;
173
(1):
1-6
-
Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis.
Weinberg AD,
Bourdette DN, Sullivan TJ, Lemon M, Wallin JJ, Maziarz R, Davey M, Palida F, Godfrey W, Engleman E, Fulton RJ, Offner H, Vandenbark AA.
Nat Med.
1996;
2
(2):
183-9
-
Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells.
Hsu FJ,
Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R.
Nat Med.
1996;
2
(1):
52-8
-
Cellular and molecular basis of human gamma delta T cell activation. Role of accessory molecules in alloactivation.
Takamizawa M,
Fagnoni F, Mehta-Damani A, Rivas A, Engleman EG.
J Clin Invest.
1995;
95
(1):
296-303
-
Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial.
van Vollenhoven RF,
Engleman EG, McGuire JL.
Arthritis Rheum.
1995;
38
(12):
1826-31
-
Generation of antigen-specific CD4+ T cell lines from naive precursors.
Mehta-Damani A,
Markowicz S, Engleman EG.
Eur J Immunol.
1995;
25
(5):
1206-11
-
Prevention of AIDS transmission through screening of the blood supply.
Galel SA,
Lifson JD, Engleman EG.
Annu Rev Immunol.
1995:
13
201-27
-
Requirement for natural killer cells in the induction of cytotoxic T cells.
Kos FJ,
Engleman EG.
J Immunol.
1995;
155
(2):
578-84
-
Role of B70/B7-2 in CD4+ T-cell immune responses induced by dendritic cells.
Fagnoni FF,
Takamizawa M, Godfrey WR, Rivas A, Azuma M, Okumura K, Engleman EG.
Immunology.
1995;
85
(3):
467-74
-
V7, a novel leukocyte surface protein that participates in T cell activation. I. Tissue distribution and functional studies.
Rivas A,
Ruegg CL, Zeitung J, Laus R, Warnke R, Benike C, Engleman EG.
J Immunol.
1995;
154
(9):
4423-33
-
V7, a novel leukocyte surface protein that participates in T cell activation. II. Molecular cloning and characterization of the V7 gene.
Ruegg CL,
Rivas A, Madani ND, Zeitung J, Laus R, Engleman EG.
J Immunol.
1995;
154
(9):
4434-43
-
An open study of dehydroepiandrosterone in systemic lupus erythematosus.
van Vollenhoven RF,
Engleman EG, McGuire JL.
Arthritis Rheum.
1994;
37
(9):
1305-10
-
Generation of antigen-specific CD8+ CTLs from naive precursors.
Mehta-Damani A,
Markowicz S, Engleman EG.
J Immunol.
1994;
153
(3):
996-1003
-
Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor.
Godfrey WR,
Fagnoni FF, Harara MA, Buck D, Engleman EG.
J Exp Med.
1994;
180
(2):
757-62
-
Degradation of CD4 following phorbol-induced internalization in human T lymphocytes. Evidence for distinct endocytic routing of CD4 and CD3.
Ruegg CL,
Rajasekar S, Stein BS, Engleman EG.
J Biol Chem.
1992;
267
(26):
18837-43
-
Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T cells.
Suzuki T,
Suzuki N, Daynes RA, Engleman EG.
Clin Immunol Immunopathol.
1991;
61
(2 Pt 1):
202-11
-
Early activation events render T cells susceptible to HIV-1-induced syncytia formation. Role of protein kinase C.
Mohagheghpour N,
Chakrabarti R, Stein BS, Gowda SD, Engleman EG.
J Biol Chem.
1991;
266
(11):
7233-8
-
Evidence for the involvement of CD56 molecules in alloantigen-specific recognition by human natural killer cells.
Suzuki N,
Suzuki T, Engleman EG.
J Exp Med.
1991;
173
(6):
1451-61
-
Interrelationships between mevalonate metabolism and the mitogenic signaling pathway in T lymphocyte proliferation.
Chakrabarti R,
Engleman EG.
J Biol Chem.
1991;
266
(19):
12216-22
-
Mechanism of HIV-1 entry into CD4+ T cells.
Stein BS,
Engleman EG.
Adv Exp Med Biol.
1991:
300
71-86; discussion 87-96
-
Alloantigen-specific cytotoxic clones bearing the alpha,beta T cell antigen receptor but not CD4 or CD8 molecules.
Rivas A,
Koide J, Laus R, Engleman EG.
J Immunol.
1990;
145
(2):
470-6
-
Anti-DNA antibody production by CD5+ and CD5- B cells of patients with systemic lupus erythematosus.
Suzuki N,
Sakane T, Engleman EG.
J Clin Invest.
1990;
85
(1):
238-47
-
Differences in surface phenotype and mechanism of action between alloantigen-specific CD8+ cytotoxic and suppressor T cell clones.
Koide J,
Engleman EG.
J Immunol.
1990;
144
(1):
32-40
-
Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro.
Markowicz S,
Engleman EG.
J Clin Invest.
1990;
85
(3):
955-61
-
Identification of an immunostimulating protein from Mycobacterium leprae.
Mohagheghpour N,
Munn MW, Gelber RH, Engleman EG.
Infect Immun.
1990;
58
(3):
703-10
-
Impaired immunity in AIDS. The mechanisms responsible and their potential reversal by antiviral therapy.
Ruegg CL,
Engleman EG.
Ann N Y Acad Sci.
1990:
616
307-17
-
Intracellular processing of the gp160 HIV-1 envelope precursor. Endoproteolytic cleavage occurs in a cis or medial compartment of the Golgi complex.
Stein BS,
Engleman EG.
J Biol Chem.
1990;
265
(5):
2640-9
-
Natural killer lines and clones with apparent antigen specificity.
Suzuki N,
Bianchi E, Bass H, Suzuki T, Bender J, Pardi R, Brenner CA, Larrick JW, Engleman EG.
J Exp Med.
1990;
172
(2):
457-62
-
A subset of human rosetted lymphocytes contains previously unidentified histamine.
Khan MM,
Fishwild DM, Melmon KL, Coutre S, Engleman EG, Bauer JA.
Clin Immunol Immunopathol.
1989;
52
(2):
147-59
-
Acquired immune tolerance to cadaveric renal allografts. A study of three patients treated with total lymphoid irradiation.
Strober S,
Dhillon M, Schubert M, Holm B, Engleman E, Benike C, Hoppe R, Sibley R, Myburgh JA, Collins G.
N Engl J Med.
1989;
321
(1):
28-33
-
Differences in surface phenotype between cytolytic and non-cytolytic CD4+ T cells. MHC class II-specific cytotoxic T lymphocytes lack Leu 8 antigen and express CD2 in high density.
Takada S,
Koide J, Engleman EG.
J Immunol.
1989;
142
(9):
3038-44
-
Evidence for involvement of the gamma, delta T cell antigen receptor in cytotoxicity mediated by human alloantigen-specific T cell clones.
Rivas A,
Koide J, Cleary ML, Engleman EG.
J Immunol.
1989;
142
(6):
1840-6
-
Evidence that T cell activation is required for HIV-1 entry in CD4+ lymphocytes.
Gowda SD,
Stein BS, Mohagheghpour N, Benike CJ, Engleman EG.
J Immunol.
1989;
142
(3):
773-80
-
Evidence that cytotoxic lymphocytes alter and traverse allogeneic endothelial cell monolayers.
Bender JR,
Pardi R, Kosek J, Engleman EG.
Transplantation.
1989;
47
(6):
1047-53
-
Expression and processing of human immunodeficiency virus type 1 gag and pol genes by cells infected with a recombinant vaccinia virus.
Gowda SD,
Stein BS, Steimer KS, Engleman EG.
J Virol.
1989;
63
(3):
1451-4
-
Identification of protein intermediates in the processing of the p55 HIV-1 gag precursor in cells infected with recombinant vaccinia virus.
Gowda SD,
Stein BS, Engleman EG.
J Biol Chem.
1989;
264
(15):
8459-62
-
Natural killer (NK)-like cytotoxic activity of allospecific T cell receptor-gamma,delta+ T cell clones. Distinct receptor-ligand interactions mediate NK-like and allospecific cytotoxicity.
Koide J,
Rivas A, Engleman EG.
J Immunol.
1989;
142
(12):
4161-8
-
Activation of HLA-restricted EBV-specific cytotoxic T cells does not require CD4+ (helper) T cells or exogenous cytokines.
Fishwild DM,
Benike CJ, Engleman EG.
J Immunol.
1988;
140
(6):
1994-8
-
CD4 molecules are associated with the antigen receptor complex on activated but not resting T cells.
Rivas A,
Takada S, Koide J, Sonderstrup-McDevitt G, Engleman EG.
J Immunol.
1988;
140
(9):
2912-8
-
Clinical and immunological studies of cadaveric renal transplant recipients given total-lymphoid irradiation and maintained on low-dose prednisone.
Saper V,
Chow D, Engleman ED, Hoppe RT, Levin B, Collins G, Strober S.
Transplantation.
1988;
45
(3):
540-6
-
Human T cell leukemia virus-I-associated T-suppressor cell inhibition of erythropoiesis in a patient with pure red cell aplasia and chronic T gamma-lymphoproliferative disease.
Levitt LJ,
Reyes GR, Moonka DK, Bensch K, Miller RA, Engleman EG.
J Clin Invest.
1988;
81
(2):
538-48
-
Evidence for an association between CD8 molecules and the T cell receptor complex on cytotoxic T cells.
Takada S,
Engleman EG.
J Immunol.
1987;
139
(10):
3231-5
-
Human monoclonal antibodies to Rh0(D).
Foung SK,
Blunt JA, Wu PS, Ahearn P, Winn LC, Engleman EG, Grumet FC.
Vox Sang.
1987;
53
(1):
44-7
-
Lymphocyte subsets differentially induce class II human leukocyte antigens on allogeneic microvascular endothelial cells.
Pardi R,
Bender JR, Engleman EG.
J Immunol.
1987;
139
(8):
2585-92
-
T cell regulatory disturbances in the rheumatic diseases.
Alpert SD,
Koide J, Takada S, Engleman EG.
Rheum Dis Clin North Am.
1987;
13
(3):
431-45
Help